BR9909393A - Agente antitumor, uso de um derivado de estilbeno e um composto de coordenação de platina, e, processo para o tratamento ou melhoramento de um tumor - Google Patents

Agente antitumor, uso de um derivado de estilbeno e um composto de coordenação de platina, e, processo para o tratamento ou melhoramento de um tumor

Info

Publication number
BR9909393A
BR9909393A BR9909393-6A BR9909393A BR9909393A BR 9909393 A BR9909393 A BR 9909393A BR 9909393 A BR9909393 A BR 9909393A BR 9909393 A BR9909393 A BR 9909393A
Authority
BR
Brazil
Prior art keywords
tumor
platinum coordination
treatment
coordination compound
improvement
Prior art date
Application number
BR9909393-6A
Other languages
English (en)
Inventor
Yoshihiro Moringa
Yukio Nihei
Yasuyo Suga
Manabu Suzuki
Kazuo Ohishi
Akira Okano
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of BR9909393A publication Critical patent/BR9909393A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"AGENTE ANTITUMOR, USO DE UM DERIVADO DE ESTILBENO E UM COMPOSTO DE COORDENAçãO DE PLATINA, E, PROCESSO PARA O TRATAMENTO OU MELHORAMENTO DE UM TUMOR" Agentes antitumor contendo como os ingredientes ativos derivados de estilbeno e composto de coordenação de platina. Devido ao uso combinado desses dois tipos de ingredientes ativos, esses agentes são previstos de utilidade como agentes antitumores altamente seguros apresentando uma atividade antitumor melhorada de forma sinérgica. Quando utilizado juntamente com os compostos de coordenação de platina acima, a atividade antitumor inerente dos derivados de estilbeno é ainda mais acentuada proporcianando agentes antitumor que possuem uma eficiência melhorada e que são particularmente adequados para o tratamento de tumores malignos. Além disso, é proporcionada a utilização desses ingredientes ativos como drogas ou como terapia, etc., bem como processos para tal.
BR9909393-6A 1998-04-03 1999-03-29 Agente antitumor, uso de um derivado de estilbeno e um composto de coordenação de platina, e, processo para o tratamento ou melhoramento de um tumor BR9909393A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10870898 1998-04-03
JP22984398 1998-08-14
PCT/JP1999/001633 WO1999051246A1 (fr) 1998-04-03 1999-03-29 Agents antitumoraux

Publications (1)

Publication Number Publication Date
BR9909393A true BR9909393A (pt) 2000-12-26

Family

ID=26448545

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909393-6A BR9909393A (pt) 1998-04-03 1999-03-29 Agente antitumor, uso de um derivado de estilbeno e um composto de coordenação de platina, e, processo para o tratamento ou melhoramento de um tumor

Country Status (19)

Country Link
US (6) US6462087B1 (pt)
EP (1) EP1068870B1 (pt)
JP (3) JP4470321B2 (pt)
KR (1) KR100598474B1 (pt)
CN (1) CN1140272C (pt)
AT (1) ATE328599T1 (pt)
AU (1) AU747599C (pt)
BR (1) BR9909393A (pt)
CA (1) CA2326761C (pt)
DE (1) DE69931766T2 (pt)
DK (1) DK1068870T3 (pt)
ES (1) ES2267255T3 (pt)
HU (1) HUP0102521A3 (pt)
IL (1) IL138723A (pt)
NO (1) NO328704B1 (pt)
NZ (1) NZ507221A (pt)
PT (1) PT1068870E (pt)
RU (1) RU2215525C2 (pt)
WO (1) WO1999051246A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
PT1068870E (pt) * 1998-04-03 2006-10-31 Ajinomoto Kk Agentes antitumorais
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
CA2433417C (en) * 2001-01-18 2010-10-19 Welichem Biotech Inc. Novel 1,2-diphenylethene derivatives for treatment of immune diseases
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
DK1407784T3 (da) * 2001-06-25 2011-02-28 Ajinomoto Kk Antitumormidler
KR20030018800A (ko) * 2001-08-31 2003-03-06 주식회사 프로메디텍 시토크롬 피450 1비1 억제활성을 갖는 페닐환 유도체 및약학적으로 허용가능한 그의 염, 그의 제조방법 및 이를함유하는 조성물
US7371773B2 (en) * 2003-02-04 2008-05-13 Kabushiki Kaisha Yakult Honsha Breast cancer resistance protein (BCRP) inhibitor
DK2368553T3 (en) * 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
AU2006214164B2 (en) * 2005-02-17 2010-12-09 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
US9662390B2 (en) * 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
WO2008121348A2 (en) * 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
ES2493590T3 (es) 2007-03-29 2014-09-12 Wyeth Llc Antagonistas de receptores opioides periféricos y usos de los mismos
US8095816B1 (en) 2007-04-05 2012-01-10 Marvell International Ltd. Processor management using a buffer
US8443187B1 (en) 2007-04-12 2013-05-14 Marvell International Ltd. Authentication of computing devices in server based on mapping between port identifier and MAC address that allows actions-per-group instead of just actions-per-single device
US8321706B2 (en) 2007-07-23 2012-11-27 Marvell World Trade Ltd. USB self-idling techniques
DK2219451T3 (en) 2007-11-21 2015-01-12 Oxigene Inc A method for the treatment of hematopoietic neoplasms
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) * 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
BRPI0921249A8 (pt) 2008-11-14 2018-12-04 Histogen Inc uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterápico na preparação de uma composição, e composições para o tratamento do cãncer
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib
FR2953518B1 (fr) 2009-12-03 2012-01-20 Sanofi Aventis Procede de preparation d'un derive de combretastatine
EP2397135A1 (en) 2010-06-18 2011-12-21 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2481404A1 (en) 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
KR20130088753A (ko) 2010-06-18 2013-08-08 사노피 옴브라불린, 탁산 유도체 및 백금 유도체를 포함하는 항종양 조합물
EP2407161A1 (en) 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
FR2968557A1 (fr) 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
JP2014512337A (ja) 2011-01-28 2014-05-22 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション スチルベン類似体およびがんを処置する方法
AU2012275841A1 (en) 2011-06-27 2014-01-16 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
US9141394B2 (en) 2011-07-29 2015-09-22 Marvell World Trade Ltd. Switching between processor cache and random-access memory
FR2978662A1 (fr) * 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
US9436629B2 (en) 2011-11-15 2016-09-06 Marvell World Trade Ltd. Dynamic boot image streaming
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US9575768B1 (en) 2013-01-08 2017-02-21 Marvell International Ltd. Loading boot code from multiple memories
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
US9458086B1 (en) 2013-07-03 2016-10-04 University Of South Florida (A Florida Non-Profit Corporation) Compositions and methods for adipocyte modulation
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN107311846B (zh) * 2017-07-25 2022-05-13 上海华理生物医药股份有限公司 偕二氟乙基取代的二苯乙烯和二苯乙烷类衍生物及其制备方法和应用
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH588505A5 (pt) * 1972-06-08 1977-06-15 Research Corp
JPS56103192A (en) * 1980-01-18 1981-08-18 Yoshinori Kitani Novel platinum complex
US4935450A (en) * 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5561136A (en) * 1990-12-13 1996-10-01 Merrell Pharmaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
GB9106177D0 (en) * 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5525622A (en) * 1991-08-28 1996-06-11 Bayer Aktiengesellschaft Substituted pyrazolines
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5844001A (en) * 1993-02-26 1998-12-01 Research Development Foundation Combination platinum chemotherapeutic/antiestrogen therapy for human cancers
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US5731353A (en) * 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
JP3163391B2 (ja) 1995-03-07 2001-05-08 味の素株式会社 スチルベン誘導体及びそれを含有する制癌剤
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
AU6906396A (en) * 1995-08-30 1997-03-19 Arch Development Corporation Methods and compositions including dna damaging agents and tyrosine kinase inhibitors or activators
WO1998033481A1 (en) 1997-02-05 1998-08-06 Pharmacia & Upjohn Company Lipid complexes and liposomes of highly insoluble platinum complexes
PT1068870E (pt) * 1998-04-03 2006-10-31 Ajinomoto Kk Agentes antitumorais
CZ292170B6 (cs) 1998-08-14 2003-08-13 Pliva-Lachema A.S. Farmaceutická kompozice s protinádorovým účinkem na bázi carboplatiny
GB9903403D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
GB9918912D0 (en) * 1999-08-12 1999-10-13 Angiogene Pharm Ltd New stilbenes with vascular damaging activity
EP1351573A4 (en) * 2000-12-22 2007-03-28 Bristol Myers Squibb Co METHOD FOR MODULATING TUMOR WATCHTOWER AND METASTASIS
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
DK1407784T3 (da) * 2001-06-25 2011-02-28 Ajinomoto Kk Antitumormidler

Also Published As

Publication number Publication date
ES2267255T3 (es) 2007-03-01
NO20004911L (no) 2000-12-04
KR100598474B1 (ko) 2006-07-11
EP1068870A4 (en) 2003-02-12
US6462087B1 (en) 2002-10-08
DE69931766T2 (de) 2007-05-31
AU747599B2 (en) 2002-05-16
RU2215525C2 (ru) 2003-11-10
DK1068870T3 (da) 2006-10-02
IL138723A (en) 2005-11-20
ATE328599T1 (de) 2006-06-15
JP5120368B2 (ja) 2013-01-16
EP1068870A1 (en) 2001-01-17
IL138723A0 (en) 2001-10-31
US20020193362A1 (en) 2002-12-19
JP2010053156A (ja) 2010-03-11
US20050281892A1 (en) 2005-12-22
US7973076B2 (en) 2011-07-05
US6992106B2 (en) 2006-01-31
CN1140272C (zh) 2004-03-03
AU2960799A (en) 1999-10-25
NO328704B1 (no) 2010-04-26
CA2326761A1 (en) 1999-10-14
NO20004911D0 (no) 2000-09-29
PT1068870E (pt) 2006-10-31
CN1303294A (zh) 2001-07-11
DE69931766D1 (de) 2006-07-20
JP4470321B2 (ja) 2010-06-02
US20090093540A1 (en) 2009-04-09
JP2009275052A (ja) 2009-11-26
HUP0102521A3 (en) 2003-08-28
JP5056816B2 (ja) 2012-10-24
AU747599C (en) 2003-06-05
US7655696B2 (en) 2010-02-02
EP1068870B1 (en) 2006-06-07
US20100069486A1 (en) 2010-03-18
WO1999051246A1 (fr) 1999-10-14
HUP0102521A2 (hu) 2001-10-28
CA2326761C (en) 2008-02-19
KR20010042399A (ko) 2001-05-25
NZ507221A (en) 2003-04-29
US20020193434A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
BR9909393A (pt) Agente antitumor, uso de um derivado de estilbeno e um composto de coordenação de platina, e, processo para o tratamento ou melhoramento de um tumor
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR0115446A (pt) Processos para tratamento de condições associadas a quinase p38 e compostos pirrolotriazina úteis como inibidores de quinase
GB0022438D0 (en) Organic Compounds
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0317717A (pt) Composto, composição farmacêutica, uso de um composto, método para tratar um humano sofrendo de uma doença, e, processo para a preparação de um composto
DE69710065T2 (de) Androsten-derivate
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
BR0110837A (pt) Quimioterapia de combinação
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
ZA8665B (en) Dopamine-beta-hydroxylase inhibitors
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
KR960700734A (ko) 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers)
BRPI0410657A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
ATE18761T1 (de) Carbamoyloxybenzhydrol-derivate, ihre herstellung und ihre pharmazeutische zusammensetzungen.
RU94024337A (ru) Антиметастатическое средство
ES2118831T3 (es) Preparaciones que contienen carboplatino o lobaplatino para la terapia antitumoral y/o para la estimulacion del sistema hemotopoyetico.
ATE346080T1 (de) Steroid-verbindungen mit anti-tumoraler wirkung
EP1011672A4 (en) CONNECTIONS WITH ANALGETIC EFFECT AND COMPILATIONS THAT CONTAIN THEM
KR960022546A (ko) 신규 백금 착화합물 및 이를 함유하는 악성 종양치료제
TH55701A (th) อนุพันธ์ 1,2-ไดเฟนิลพิโรล, การเตรียมสารเหล่านี้และการใช้สารเหล่านี้ในการรักษาโรค

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O, 10 (VIII ), 13 , 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]